5-ethyl-5-(pentan-2-yl)-1,3-diazinane-2,4,6-trione

• ChemBase编号: 197
• 分子式: C11H18N2O3
• 平均质量: 226.27222
• 单一同位素质量: 226.13174245
• SMILES: O=C1NC(=O)NC(=O)C1(C(CCC)C)CC
• Canonical SMILES: CCCC(C1(CC)C(=O)NC(=O)NC1=O)C
• InChI: InChI=1S/C11H18N2O3/c1-4-6-7(3)11(5-2)8(14)12-10(16)13-9(11)15/h7H,4-6H2,1-3H3,(H2,12,13,14,15,16)
• InChIKey: WEXRUCMBJFQVBZ-UHFFFAOYSA-N

名称和登记号

名称

• IUPAC标准名: 5-ethyl-5-(pentan-2-yl)-1,3-diazinane-2,4,6-trione
• IUPAC传统名: @pentobarbital; pentobarbital
• 商标名: Dorsital; Ethaminal; Mebubarbital; Mebumal; Nebralin; Nembutal; Nembutal Sodium; Neodorm; Rivadorm
• 别名: Pentobarbital Sodium; Pentabarbitone; Pentabarbital; Pentobarbitone; Pentobarbiturate; Pentobarbituric acid; Sodium Pentobarbital; Pentobarbital; 5-Ethyl-5-(1-methylbutyl)-2,4,6-trioxohexahydropyrimidine; Nembutal; Pentobarbital

登记号

• CAS号: 76-74-4
• EC号: 200-983-8
• MDL号: MFCD00057561
• PubChem SID: 160963660; 46508399
• PubChem CID: 4737
• CHEBI ID: 7983
• ATC码: QN51AA01; N05CA01
• CHEMBL: 448
• Chemspider ID: 4575
• DrugBank ID: DB00312
• KEGG ID: D00499
• 美国药典/FDA物质标识码: I4744080IR
• 维基百科标题: Pentobarbital
• Medline Plus: a682416

理论计算性质

JChem

• Acid pKa: 8.482022
• 质子受体: 3
• 质子供体: 2
• LogD (pH = 5.5): 1.892804
• LogD (pH = 7.4): 1.8591163
• Log P: 1.8932513
• 摩尔折射率: 58.0029 cm^3
• 极化性: 22.809618 Å^3
• 极化表面积: 75.27 Å^2
• 可自由旋转的化学键: 4
• 里宾斯基五规则: true

ALOGPS 2.1

• Log P: 2.16
• LOG S: -2.42
• 溶解度: 8.64e-01 g/l

分子性质

理化性质

• 溶解度: 679 mg/L
• 疏水性(logP): 2.1

安全信息

• RTECS编号: CQ5775000
• 欧盟危险性物质标志: 有毒(Toxic) (T)
• 联合国危险货物编号: 2811
• 德国WGK号: 3
• 联合国危险货物等级: 6.1
• 联合国危险货物包装类别(PG): 3
• 危险公开号: 63-25
• 安全公开号: 22-36/37/39-45
• GHS危险品标识: GHS06; GHS08
• GHS警示词: Danger
• GHS危险声明: H301-H361
• GHS警示性声明: P281-P301 + P310
• 个人保护装置: Eyeshields, Faceshields, full-face particle respirator type N100 (US), Gloves, respirator cartridge type N100 (US), type P1 (EN143) respirator filter, type P3 (EN 143) respirator cartridges
• RID/ADR: UN 2811 6.1/PG 3
• 毒品管制信息: USDEA Schedule II; Home Office Schedule 3; psychotrope; kontrollierte Droge in Deutschland; regulated under CDSA - not available from Sigma-Aldrich Canada

药理学性质

• 给药途径: Oral, Intravenous, Intramuscular, Rectal; also Intraperitoneal & Intracardiac (for animal euthanasia)
• 生物利用度: 70-90% oral; 90% rectal
• 排泄: Renal
• 半衰期: 15-48 hours
• 代谢: Hepatic
• 蛋白结合率: 20-45%
• 法定药品分级: USA: Schedule II (oral and parenteral); Schedule III (rectal), UK: Class B Controlled Substance
• 妊娠期药物分类: D (USA)

产品相关信息

• Empirical Formula (Hill Notation): C11H18N2O3

详细说明

DrugBank - DB00312

• Drug Groups: approved
• Description: A short-acting barbiturate that is effective as a sedative and hypnotic (but not as an anti-anxiety) agent and is usually given orally. It is prescribed more frequently for sleep induction than for sedation but, like similar agents, may lose its effectiveness by the second week of continued administration. (From AMA Drug Evaluations Annual, 1994, p236)
• Indication: For the short-term treatment of insomnia.
• Pharmacology: Pentobarbital, a barbiturate, is used for the treatment of short term insomnia. It belongs to a group of medicines called central nervous system (CNS) depressants that induce drowsiness and relieve tension or nervousness. Little analgesia is conferred by barbiturates; their use in the presence of pain may result in excitation.
• Toxicity: Symptoms of an overdose typically include sluggishness, incoordination, difficulty in thinking, slowness of speech, faulty judgment, drowsiness or coma, shallow breathing, staggering, and in severe cases coma and death.
• Affected Organisms: Humans and other mammals
• Biotransformation: by hepatic microsomal enzyme system
• Absorption: Barbiturates are absorbed in varying degrees following oral, rectal, or parenteral administration.
• Half Life: 5 to 50 hours (dose dependent)
• Elimination: Barbiturates are metabolized primarily by the hepatic microsomal enzyme system, and the metabolic products are excreted in the urine, and less commonly, in the feces. Approximately 25 to 50 percent of a dose of aprobarbital or phenobarbital is eliminated unchanged in the urine, whereas the amount of other barbiturates excreted unchanged in the urine is negligible.
• References: Knodell RG, Spector MH, Brooks DA, Keller FX, Kyner WT: Alterations in pentobarbital pharmacokinetics in response to parenteral and enteral alimentation in the rat. Gastroenterology. 1980 Dec;79(6):1211-6. [Pubmed]
• External Links: Wikipedia; RxList; Drugs.com

参考文献

• Knodell RG, Spector MH, Brooks DA, Keller FX, Kyner WT: Alterations in pentobarbital pharmacokinetics in response to parenteral and enteral alimentation in the rat. Gastroenterology. 1980 Dec;79(6):1211-6. Pubmed